Rongchang Biology: Vedolizumab has been approved for a new indication and will be launched on the market.

Rongchang Biotechnology announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the new indication of Vedolizumab for the treatment of breast cancer with low HER2 expression and liver metastasis. This is the fourth approved indication for Vedolizumab in the country. Vedolizumab is indicated for the treatment of adult patients with inoperable or metastatic HER2-low breast cancer who have received at least one systemic therapy in the metastatic disease stage, or who have relapsed within 12 months after adjuvant chemotherapy or completion of adjuvant chemotherapy.